17 Jun With continued IU Ventures’ investment, Indiana life sciences startup Confluence Pharmaceuticals seeks to treat autism, fragile X syndrome impairments
FOR IMMEDIATE RELEASE Carmel, Ind. -- With recent investments from IU Ventures totaling $500,000, an Indiana-based life sciences company is accelerating its efforts to find a treatment solution for those afflicted with autism spectrum disorder and fragile X syndrome. IU Ventures, Indiana University's early-stage venture and angel...
